NASDAQ:INM

InMed Pharmaceuticals - INM Stock Forecast, Price & News

$2.20

+0.12 (+5.77%)

(As of 02/3/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.85
▼
$2.24
50-Day Range: $1.32
▼
$2.74
52-Week Range: $1.23
▼
$35.50

Volume: 477,684 shs
Average Volume: 866,755 shs
Market Capitalization: $2.07 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About InMed Pharmaceuticals (NASDAQ:INM) Stock

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INM Stock News Headlines

January 11, 2023 | benzinga.com

This Company's Rare Cannabinoids May Hold Promise In The Treatment Of Neurodegenerative Diseases Like Alzheimer's

January 2, 2023 | marketwatch.com

Biosynthesis of Cannabinoids Market Size and Share Likely to Grow with CAGR Status and Industry Revenue Forecast by 2023-2029

February 5, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

December 15, 2022 | finance.yahoo.com

InMed Announces Results of 2022 Annual General Meeting

November 18, 2022 | marketwatch.com

InMed Pharmaceuticals Shares Drop 19% After Private Placement Prices

November 17, 2022 | finance.yahoo.com

InMed Provides Update on Management Changes

November 16, 2022 | marketwatch.com

InMed Pharmaceuticals Shares Rise on New Cannabinoid Study on Neurodegenerative Diseases

November 16, 2022 | finance.yahoo.com

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding

February 5, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

November 10, 2022 | finance.yahoo.com

Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022

October 26, 2022 | finance.yahoo.com

InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

September 19, 2022 | finance.yahoo.com

InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

September 14, 2022 | marketwatch.com

InMed Pharmaceuticals Shares Drop After Monday Rise

September 12, 2022 | seekingalpha.com

InMed adds 63% on rising volume after private placement

September 12, 2022 | markets.businessinsider.com

S&P 500 Rises 1%, InMed Pharmaceuticals Shares Spike Higher

September 12, 2022 | msn.com

Why InMed Pharmaceuticals Stock Is Rising Today

September 9, 2022 | seekingalpha.com

InMed climbs 23% amid plans to focus on pharma drug development

July 25, 2022 | msn.com

InMed Provides An Update On Phase 2 Clinical Trial Investigating Cannabinol Cream For Epidermolysis Bullosa

June 9, 2022 | baystreet.ca

Top 5 Ways to Profit from a Potential THCV Boom

June 2, 2022 | seekingalpha.com

InMed Pharmaceuticals announces $5M registered direct and private placement offerings

June 2, 2022 | finance.yahoo.com

InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

May 17, 2022 | realmoney.thestreet.com

InMed Pharmaceuticals Inc. (INM)

May 13, 2022 | finance.yahoo.com

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

May 13, 2022 | finance.yahoo.com

InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates

May 13, 2022 | benzinga.com

InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition

May 5, 2022 | ca.finance.yahoo.com

Stocks in play: InMed Pharmaceuticals Inc

May 3, 2022 | uk.investing.com

InMed Pharmaceuticals: Notable Launches Of High-Value Rare Cannabinoids

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INM Company Calendar

Last Earnings: 11/11/2022
Today: 2/05/2023
Next Earnings (Estimated): 2/13/2023
Fiscal Year End: 6/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INM
CUSIP: N/A
CIK: 1728328
Web: www.inmedpharma.com
Phone: 604-669-7207
Fax: N/A
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($30.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,600,000.00
Net Margins: -1,356.41%
Pretax Margin: -1,355.85%
Return on Equity: -169.59%
Return on Assets: -123.00%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 3.52
Quick Ratio: 2.98

Sales & Book Value

Annual Sales: $1.09 million
Price / Sales: 1.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $13.95 per share
Price / Book: 0.16

Miscellaneous

Outstanding Shares: 940,000
Free Float: 915,000
Market Cap: $2.07 million
Optionable: Not Optionable
Beta: -0.24

Key Executives

Mr. Eric A. Adams B.S. Chem. (Age 60)
M.I.B., Pres, CEO & Director
Comp: $363.17k

Ms. Alexandra Diane-Janet Mancini M.Sc. (Age 70)
Sr. VP of Clinical & Regulatory Affairs
Comp: $261.03k

Dr. Eric Chih-Hsien Hsu (Age 53)
Sr. VP of Preclinical R&D
Comp: $253.46k

Dr. Sazzad Hossain M.Sc. (Age 65)
Ph.D., Co-Founder

Mr. Jonathan R. Tegge (Age 33)
Interim Chief Financial Officer

Mr. Michael Woudenberg P.Eng. (Age 54)
Chief Operating Officer

Ms. Sarah Li CPA
CGA, VP of Accounting & Controller

Colin Clancy
Sr. Director of Investor Relations

Mr. Jerry P. Griffin
VP of Sales & Marketing

Dr. Shane A. Johnson Ph.D.
Sr. VP & GM of BayMedica

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INM Stock - Frequently Asked Questions

Should I buy or sell InMed Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INM, but not buy additional shares or sell existing shares.
View INM analyst ratings or view top-rated stocks.
How have INM shares performed in 2023?: InMed Pharmaceuticals' stock was trading at $2.02 at the beginning of the year. Since then, INM shares have increased by 8.9% and is now trading at $2.20.
View the best growth stocks for 2023 here.
When is InMed Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our INM earnings forecast.
How were InMed Pharmaceuticals' earnings last quarter?: InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its earnings results on Friday, November, 11th. The company reported ($4.06) EPS for the quarter, beating analysts' consensus estimates of ($4.25) by $0.19. The business earned $0.32 million during the quarter. InMed Pharmaceuticals had a negative net margin of 1,356.41% and a negative trailing twelve-month return on equity of 169.59%.

When did InMed Pharmaceuticals' stock split?: Shares of InMed Pharmaceuticals reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What is InMed Pharmaceuticals' stock symbol?: InMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "INM."
How do I buy shares of InMed Pharmaceuticals?: Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is InMed Pharmaceuticals' stock price today?: One share of INM stock can currently be purchased for approximately $2.20.
How much money does InMed Pharmaceuticals make?: InMed Pharmaceuticals (NASDAQ:INM) has a market capitalization of $2.07 million and generates $1.09 million in revenue each year. The company earns $-18,600,000.00 in net income (profit) each year or ($30.98) on an earnings per share basis.
How can I contact InMed Pharmaceuticals?: The official website for the company is www.inmedpharma.com. The company can be reached via phone at 604-669-7207 or via email at info@inmedpharma.com.

This page (NASDAQ:INM) was last updated on 2/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial